{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:26Z","timestamp":1793914046691,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017590","name":"University Hospital Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.029","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:43:39Z","timestamp":1789667019000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["iMTSS: An Integrated Framework for Biology- and Patient-Driven Prognosis in Myelofibrosis Undergoing Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Salit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-4329","authenticated-orcid":false,"given":"Nils","family":"Leimk\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-4198","authenticated-orcid":false,"given":"Massimiliano","family":"Gambella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-7289","authenticated-orcid":false,"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0001","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2026.09.029_bib0002","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kroger","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.029_bib0003","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.15407","article-title":"Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT","volume":"182","author":"McLornan","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hernandez-Boluda","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.029_bib0005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/ajh.26654","article-title":"Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis","volume":"97","author":"Perram","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.029_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000921","article-title":"Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.029_bib0007","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S2352-3026(24)00067-X","article-title":"Methodological challenges in the development of endpoints for myelofibrosis clinical trials","volume":"11","author":"Barosi","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.029_bib0008","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jtct.2026.09.029_bib0009","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.029_bib0010","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.2025031366","article-title":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"148","author":"Mora","year":"2026","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2026.09.029_bib0012","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.2024027287","article-title":"Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis","volume":"145","author":"Hernandez-Boluda","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2026.09.029_bib0013","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.029_bib0014","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.jtct.2026.09.029_bib0015","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/bloodadvances.2023009886","article-title":"A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR\/EBMT analysis","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.09.029_bib0016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-031-84988-6_9","article-title":"Myelofibrosis: timing of transplantation and management of splenomegaly","volume":"1475","author":"Kroger","year":"2025","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.029_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.029_bib0018","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2024014368","article-title":"Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis","volume":"9","author":"Luque Paz","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.029_bib0019","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41375-018-0185-y","article-title":"The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Fein","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.029_bib0020","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.029_bib0021","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41409-026-02842-z","article-title":"Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival","volume":"61","author":"Barbullushi","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.029_bib0022","doi-asserted-by":"crossref","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2026.09.029_bib0023","doi-asserted-by":"crossref","first-page":"q824","DOI":"10.1136\/bmj.q824","article-title":"TRIPOD+AI: an updated reporting guideline for clinical prediction models","volume":"385","author":"Cohen","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1541-0420.2010.01420.x","article-title":"Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring","volume":"67","author":"Geskus","year":"2011","journal-title":"Biometrics"},{"key":"10.1016\/j.jtct.2026.09.029_bib0025","article-title":"Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome","volume":"5","author":"Dillon","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.029_bib0026","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2013 a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.jtct.2026.09.029_bib0027","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2026.09.029_bib0028","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.029_bib0029","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa2408941","article-title":"Clearance of driver mutations after transplantation for myelofibrosis","volume":"392","author":"Gagelmann","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41409-024-02437-6","article-title":"Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"60","author":"Polverelli","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.029_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113098","article-title":"Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis","volume":"12","author":"Atagunduz","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.029_bib0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.jtct.2026.09.029_bib0033","first-page":"2901","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.029_bib0035","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0036","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/leu.2014.277","article-title":"SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation","volume":"29","author":"Bartels","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.029_bib0037","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.029_bib0038","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41409-023-02094-1","article-title":"Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","volume":"58","author":"Hernandez-Boluda","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.09.029_bib0039","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.029_bib0040","doi-asserted-by":"crossref","first-page":"1011.e1","DOI":"10.1016\/j.jtct.2024.07.026","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German registry for stem cell transplantation","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.029_bib0041","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ejh.13294","article-title":"Allogeneic stem cell transplantation for myelofibrosis patients aged >\/=65 years","volume":"103","author":"Daghia","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.029_bib0042","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.clml.2025.08.012","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in older patients aged 65 years and above with myelofibrosis","volume":"26","author":"Shahzad","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.jtct.2026.09.029_bib0043","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1182\/bloodadvances.2024013451","article-title":"Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.029_bib0044","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/ajh.70049","article-title":"Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"100","author":"Hernandez-Boluda","year":"2025","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.029_bib0045","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ajh.70244","article-title":"PTCy or ATG for matched transplantation in myelofibrosis","volume":"101","author":"Chiusolo","year":"2026","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.029_bib0046","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ajh.70288","article-title":"Decreased chronic GvHD with post-transplant cyclophosphamide versus ATG in patients with myelofibrosis allografted with an unrelated donor: a study from the Chronic Malignancies Working Party of the EBMT","volume":"101","author":"Chalandon","year":"2026","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.029_bib0047","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41409-024-02291-6","article-title":"Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation","volume":"59","author":"Rathje","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.029_bib0048","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.029_bib0049","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.27529","article-title":"Clinical and immune effects of peri-transplantation JAK inhibition for myelofibrosis","volume":"100","author":"Rathje","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600758X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600758X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:15:49Z","timestamp":1793913349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600758X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"alternative-id":["S266663672600758X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"iMTSS: An Integrated Framework for Biology- and Patient-Driven Prognosis in Myelofibrosis Undergoing Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}